Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10%
The company reflected on progress across both neurologic and gastrointestinal programs, with CEO Dr.
Immunic Inc. (IMUX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 7,652,972 | $6,746,860 | 0.27% | |
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 4,699,411 | $4,143,001 | -17% | 0.94% |
| 3. | Laurion Capital Management Benjamin A. Smith | 1,882,162 | $1,659,314 | -2% | 0.03% |
| 4. | Soleus Capital Guy Levy | 1,580,007 | $1,392,934 | -79% | 0.07% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,398,600 | $1,233,006 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.79 | 12,512 | $9,884.48 | 12,512 | 2025-06-05 | Filing | |
| $0.77 | 15,000 | $11,550.00 | 29,000 | 2025-06-04 | Filing | |
| $0.83 | 20,000 | $16,694.00 | 36,032 | 2025-06-13 | Filing | |
| $0.79 | 12,512 | $9,884.48 | 12,512 | 2025-06-05 | Filing | |
| $0.77 | 15,000 | $11,550.00 | 29,000 | 2025-06-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.62 | 650 | $10,154.89 | 278,830 | 2020-07-21 | Filing | |
| $14.44 | 5,000 | $72,200.50 | 279,480 | 2020-07-20 | Filing | |
| $15.62 | 1,300 | $20,309.77 | 362,877 | 2020-07-21 | Filing | |
| $14.44 | 5,000 | $72,200.50 | 364,177 | 2020-07-20 | Filing | |
| $6.96 | 4,400 | $30,624.00 | 10,032 | 2019-12-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,243,941 | $4,399,791 | 0.01% | |
| 2. | 5,020,337 | $2,680,860 | 0% | |
| 3. | 537,118 | $286,822 | 0% | |
| 4. | 91,450 | $48,807 | 0% | |
| 5. | 12,000 | $6,404 | 0% |
News See All
10 Stocks Under $1 That Will Explode
U.S. equity markets are beginning their 2026 journey without taking a major break from existing trends, according to Morgan Stanley CIO and chief U.S.
Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial
Immunic Inc. (NASDAQ:IMUX) is one of the best penny stocks under $1 to buy now. On June 24, Immunic reported positive long-term open-label extension/OLE data from its Phase 2 EMPhASIS trial.
12 Best Penny Stocks Under $1 to Buy Now
On July 18, Greg Tuorto of Goldman Sachs joined CNBC's 'Closing Bell' to state that the small-cap market is starting to show signs of life.
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Immunic’s Third Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic.
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Jessica Breu: Good morning, and welcome to Immunic First Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications here at Immunic.
Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript
Immunic, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.51.
Immunic, Inc. (NASDAQ:IMUX) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Immunic's Second Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
10 Best Rated Penny Stocks to Buy According to Analysts
Investing in small companies, penny stocks, micro-cap or even small-cap companies went out of fashion as soon as the financial markets started to take a beating amid interest rate hikes.
Immunic, Inc. (NASDAQ:IMUX) Q1 2023 Earnings Call Transcript
Jessica Breu: Good morning, and welcome to Immunic's First Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.